Drug Profile
Research programme: influenza virus vaccines - Redbiotec
Alternative Names: Influenza VLPs - Redbiotec; RBT 101; RBT 102; RBT 103; RBT 104Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Redbiotec
- Class Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Influenza-virus-infections in Switzerland (Parenteral)
- 23 Oct 2013 Redbiotec receives grant from EU Edufluvac project for Influenza virus vaccine development in Europe
- 13 Jan 2012 Preclinical development is ongoing in Switzerland